Absci ABSI
NASDAQ ABSI
$8.82 +0.02 (+0.23%)
As of: Sep 4, 2026 · 3:59 PM EDT

Absci (ABSI) Liabilities and Shareholders Equity (2020 - 2026)

Absci (ABSI) posted Liabilities and Shareholders Equity of $195.6 million for Q1 2026, down 9.57% sequentially from $216.3 million in Q4 2025, and down 15.85% YoY from $232.4 million in Q1 2025.

Analysis

Absci (ABSI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Absci has reported Liabilities and Shareholders Equity for 7 years, with the latest figure at $195.6 million in Q1 2026.

  • Quarterly Liabilities and Shareholders Equity fell 15.85% year-over-year to $195.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $866.8 million (down 7.48% YoY) and the FY2025 annual result came in at $216.3 million, up 1.26% from the prior year.
  • Liabilities and Shareholders Equity eased to $195.6 million in Q1 2026 per ABSI's latest filing, from $216.3 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $395.5 million in Q1 2022 and troughed at $195.6 million in Q1 2026.
  • A 5-year average of $265.0 million and a median of $245.0 million in 2025 frame the typical range for Liabilities and Shareholders Equity.
  • The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity surged 42.5% in 2022, then sank 32.31% in 2023.
  • Over 5 years, Liabilities and Shareholders Equity stood at $321.0 million in 2022, then plunged by 32.31% to $217.3 million in 2023, then declined by 1.7% to $213.6 million in 2024, then advanced by 1.26% to $216.3 million in 2025, then fell by 9.57% to $195.6 million in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $195.6 million, $216.3 million, and $245.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 Absci 1.39 Bn 1.19 Bn - 268.92 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 268.92 Mn
Mar 31, 2026 195.59 Mn
Dec 31, 2025 216.30 Mn
Sep 30, 2025 244.99 Mn
Jun 30, 2025 209.89 Mn
Mar 31, 2025 232.45 Mn
Dec 31, 2024 213.61 Mn
Sep 30, 2024 235.23 Mn
Jun 30, 2024 255.53 Mn
Mar 31, 2024 274.90 Mn
Dec 31, 2023 217.30 Mn
Sep 30, 2023 236.34 Mn
Jun 30, 2023 254.15 Mn
Mar 31, 2023 295.81 Mn
Dec 31, 2022 321.01 Mn
Sep 30, 2022 339.39 Mn
Jun 30, 2022 366.32 Mn
Mar 31, 2022 395.46 Mn
Dec 31, 2021 426.20 Mn
Sep 30, 2021 449.12 Mn